---
title: "Electrolyte Disorders"
order: 4
category: "Nephrology"
---

# Electrolyte Disorders

## Overview

Electrolyte disorders are among the most common abnormalities encountered in clinical medicine. Disturbances in sodium, potassium, calcium, magnesium, and phosphate homeostasis can range from asymptomatic laboratory findings to life-threatening emergencies. Understanding the pathophysiology and appropriate management of these disorders is essential for all clinicians.

## Sodium Disorders

### Hyponatremia

**Definition**: Serum sodium <135 mEq/L (most common electrolyte disorder)

**Severity classification**:
- Mild: 130-134 mEq/L
- Moderate: 125-129 mEq/L
- Severe: <125 mEq/L

**Symptom classification**:
- Mild symptoms: Nausea, headache, fatigue
- Moderate symptoms: Confusion, disorientation
- Severe symptoms: Seizures, coma, respiratory arrest

#### Pathophysiology

Hyponatremia represents excess water relative to sodium. Classified by volume status and serum osmolality:

**By osmolality**:
- **Hypotonic hyponatremia** (most common): Low serum osmolality (<280 mOsm/kg)
- **Isotonic hyponatremia** (pseudohyponatremia): Normal osmolality (280-295 mOsm/kg)
  - Hyperlipidemia, hyperproteinemia (lab artifact with older methods)
- **Hypertonic hyponatremia**: High osmolality (>295 mOsm/kg)
  - Hyperglycemia, mannitol, contrast

**By volume status** (hypotonic hyponatremia):

*Hypovolemic hyponatremia*:
- **Renal losses**: Diuretics, salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency
- **Extrarenal losses**: Vomiting, diarrhea, third-spacing (pancreatitis, burns)
- Urine sodium: >40 mEq/L (renal), <20 mEq/L (extrarenal)

*Euvolemic hyponatremia*:
- **SIADH** (syndrome of inappropriate ADH secretion): Most common
  - Causes: Malignancy (SCLC), CNS disorders, pulmonary disease, medications (SSRIs, carbamazepine, cyclophosphamide, opioids), postoperative state, pain, nausea
- **Hypothyroidism**
- **Adrenal insufficiency** (cortisol deficiency)
- **Primary polydipsia** (excessive water intake, overwhelms kidney excretion capacity)

*Hypervolemic hyponatremia*:
- **Heart failure**: Reduced effective arterial blood volume → ADH release
- **Cirrhosis**: Splanchnic vasodilation → ADH release
- **Nephrotic syndrome**
- **Advanced CKD**

#### Clinical Presentation

**Symptoms** (related to cerebral edema):
- Mild: Nausea, headache, lethargy, confusion
- Severe: Seizures, coma, respiratory arrest, death
- Chronic hyponatremia may be asymptomatic (CNS adaptation)

**Risk factors for severe symptoms**:
- Acute onset (<48 hours)
- Very low sodium (<120 mEq/L)
- Premenopausal women, children, elderly

#### Diagnosis

**Initial evaluation**:
1. **Measure serum osmolality**: Distinguish true vs pseudohyponatremia
2. **Assess volume status**: Physical exam, history
3. **Urine osmolality and urine sodium**:
   - Urine osm <100 mOsm/kg: Primary polydipsia
   - Urine osm >100 mOsm/kg: Check urine sodium
     - UNa <20 mEq/L: Hypovolemic (extrarenal losses) or hypervolemic (HF, cirrhosis)
     - UNa >40 mEq/L: Hypovolemic (renal losses), euvolemic (SIADH), adrenal insufficiency

**SIADH criteria**:
- Hypotonic hyponatremia
- Urine osmolality >100 mOsm/kg (inappropriately concentrated)
- Urine sodium >40 mEq/L
- Euvolemia
- Normal thyroid and adrenal function
- Not on diuretics

**Additional tests**:
- TSH (hypothyroidism)
- Morning cortisol or ACTH stimulation test (adrenal insufficiency)
- BUN, creatinine (kidney function)

#### Treatment

**Acute symptomatic hyponatremia** (seizures, coma):
- **Medical emergency**
- **3% hypertonic saline**: 100 mL bolus IV over 10 minutes, repeat up to 3 times if needed
- Goal: Raise sodium by 4-6 mEq/L (enough to stop seizures)
- Then slow correction

**Chronic or asymptomatic hyponatremia**:

*General principles*:
- **Correct slowly**: 6-8 mEq/L in 24 hours, <12 mEq/L in 48 hours
- **Avoid overcorrection**: Risk of osmotic demyelination syndrome (ODS)
- High-risk for ODS: Chronic severe hyponatremia, alcoholism, malnutrition, liver disease

*By etiology*:

**Hypovolemic**:
- **Renal losses**: Stop diuretics, replace salt and volume (IV normal saline)
- **Extrarenal losses**: IV normal saline

**Euvolemic (SIADH)**:
- **Fluid restriction**: 500-1000 mL/day (first-line)
- **Salt tablets**: Increase sodium intake
- **Furosemide + oral sodium chloride**: Promote free water excretion
- **Vaptans** (vasopressin receptor antagonists): Tolvaptan, conivaptan
  - Reserved for severe or refractory cases (risk of overcorrection)
  - Contraindicated if unable to sense or respond to thirst
- **Treat underlying cause**: Discontinue offending drugs, treat malignancy

**Hypervolemic (HF, cirrhosis)**:
- **Fluid restriction**: <1-1.5 L/day
- **Diuretics**: Loop diuretics
- **Treat underlying disease**: Optimize HF management
- Vaptans: Consider if refractory, but data limited in cirrhosis

**Primary polydipsia**:
- Behavioral modification, restrict water intake

#### Complications

**Osmotic demyelination syndrome (ODS)**:
- Caused by rapid correction of chronic severe hyponatremia
- Demyelination of pontine and extrapontine neurons
- Symptoms: Dysarthria, dysphagia, paraparesis, quadriparesis, locked-in syndrome (2-6 days after correction)
- Prevention: Correct slowly, monitor sodium q4-6h during treatment
- Treatment: No specific treatment; may improve over months, but often permanent

### Hypernatremia

**Definition**: Serum sodium >145 mEq/L

**Always indicates water deficit** (too little water relative to sodium)

#### Pathophysiology

**Mechanisms**:
- Water loss > sodium loss (most common)
- Sodium gain

**By etiology**:

*Hypovolemic hypernatremia* (water loss > sodium loss):
- **Renal losses**: Osmotic diuresis (hyperglycemia, mannitol, urea), loop diuretics
- **Extrarenal losses**: GI (diarrhea, vomiting), skin (sweating, burns), respiratory (insensible losses)
- Urine osm <300 mOsm/kg: Diabetes insipidus
- Urine osm >700 mOsm/kg: Extrarenal losses

*Euvolemic hypernatremia* (pure water loss):
- **Central diabetes insipidus**: Deficient ADH secretion
  - Causes: Pituitary surgery, trauma, tumors, infiltrative disease, idiopathic
- **Nephrogenic diabetes insipidus**: Kidney resistance to ADH
  - Causes: Chronic lithium use, hypercalcemia, hypokalemia, sickle cell, CKD, genetic
- **Insensible losses**: Respiratory, skin (fever, heat exposure)

*Hypervolemic hypernatremia* (sodium gain):
- Hypertonic saline administration
- Sodium bicarbonate infusion
- Mineralocorticoid excess (primary hyperaldosteronism)

#### Clinical Presentation

**Symptoms** (related to brain cell dehydration):
- Thirst (earliest, most sensitive)
- Lethargy, confusion, irritability
- Muscle weakness, tremor, hyperreflexia
- Seizures, coma (severe)
- Intracerebral hemorrhage (brain shrinkage, vessel rupture)

**High-risk populations**:
- Elderly (impaired thirst mechanism)
- Infants
- Hospitalized or institutionalized (limited access to water)
- Altered mental status

#### Diagnosis

**Initial evaluation**:
1. **Assess volume status**
2. **Urine osmolality**:
   - <300 mOsm/kg: Diabetes insipidus (DI)
   - >700 mOsm/kg: Extrarenal water loss or sodium gain
3. **If DI suspected**: Water deprivation test + desmopressin response
   - Central DI: Urine osm increases >50% with desmopressin
   - Nephrogenic DI: Minimal response to desmopressin

#### Treatment

**General principles**:
- **Correct water deficit**
- **Correct slowly**: 0.5 mEq/L/hr, <10 mEq/L in 24 hours (risk of cerebral edema)
- **Calculate free water deficit**:
  - Water deficit = TBW × [(current Na / 140) - 1]
  - TBW (total body water) = 0.6 × weight (kg) for men, 0.5 × weight for women

**By etiology**:

**Hypovolemic**:
- Restore volume first: IV normal saline
- Then replace water deficit: Free water (PO, NG, or IV D5W)

**Euvolemic (diabetes insipidus)**:
- **Central DI**: Desmopressin (DDAVP) 1-2 mcg SC/IV BID or 0.1-0.4 mg PO BID
- **Nephrogenic DI**:
  - Treat underlying cause (stop lithium if possible)
  - Thiazide diuretics + amiloride (paradoxically reduce urine output)
  - NSAIDs (reduce GFR, decrease urine output)
  - Low-sodium diet
- **Free water replacement**

**Hypervolemic**:
- Stop sodium sources
- Free water + diuretics (furosemide)

## Potassium Disorders

### Hyperkalemia

**Definition**: Serum potassium >5.0 mEq/L

**Severity**:
- Mild: 5.1-6.0 mEq/L
- Moderate: 6.1-6.9 mEq/L
- Severe: ≥7.0 mEq/L

#### Pathophysiology

**Mechanisms**:
- Increased intake (rare as sole cause)
- Transcellular shift (K moves from intracellular to extracellular)
- Decreased renal excretion (most common)

**Causes**:

*Pseudohyperkalemia* (lab artifact):
- Hemolysis during blood draw
- Severe leukocytosis or thrombocytosis
- Prolonged tourniquet time, fist clenching

*Transcellular shift*:
- Acidosis (non-anion gap metabolic acidosis): H+ moves in, K+ moves out
- Insulin deficiency
- Tissue breakdown: Rhabdomyolysis, tumor lysis, massive hemolysis
- Hyperkalemic periodic paralysis
- Succinylcholine, digitalis toxicity

*Decreased renal excretion*:
- **Acute or chronic kidney disease** (most common if GFR <15-20)
- **Hypoaldosteronism**: Type IV RTA, Addison's disease, aldosterone synthase deficiency
- **Medications**:
  - RAAS inhibitors: ACE-I, ARBs, aldosterone antagonists (spironolactone, eplerenone)
  - Potassium-sparing diuretics: Amiloride, triamterene
  - NSAIDs
  - Trimethoprim, pentamidine (block ENaC)
  - Calcineurin inhibitors (cyclosporine, tacrolimus)
  - Heparin (suppresses aldosterone)

*Increased intake*:
- IV potassium infusion (too rapid)
- High dietary intake (usually in setting of impaired excretion)
- Salt substitutes (KCl)

#### Clinical Presentation

**Cardiac** (most important):
- **Arrhythmias**: Life-threatening
- **ECG changes** (progressive with increasing K):
  - Peaked T waves (earliest, usually K >5.5)
  - Flattened P waves, prolonged PR interval (K >6.5)
  - Wide QRS complex (K >7.0)
  - Sine wave pattern (K >8.0)
  - Ventricular fibrillation, cardiac arrest

**Neuromuscular**:
- Muscle weakness, paralysis (ascending)
- Paresthesias

**Often asymptomatic** until severe

#### Diagnosis

**Confirm true hyperkalemia**:
- Repeat test to rule out pseudohyperkalemia
- Check for hemolysis

**Evaluate cause**:
- Kidney function (Cr, eGFR)
- Acidosis (ABG or VBG)
- Medications (review)
- Urine potassium, transtubular potassium gradient (TTKG) if cause uncertain

**ECG**: Essential to assess cardiac risk

#### Treatment

**Severity and ECG changes determine urgency**

**Severe hyperkalemia with ECG changes** (medical emergency):

1. **Stabilize cardiac membrane**:
   - **Calcium gluconate** 10% 10-20 mL (1-2 amps) IV over 2-5 minutes
   - Onset: 1-3 minutes, duration 30-60 minutes
   - Does not lower K, but protects heart
   - Repeat if ECG changes persist

2. **Shift K into cells** (temporary):
   - **Insulin** 10 units IV + **dextrose** 50 g (D50W 100 mL) IV
     - Onset: 10-20 minutes, duration 4-6 hours
     - Check glucose q1h (risk of hypoglycemia)
   - **Albuterol** 10-20 mg nebulized (or 0.5 mg IV)
     - Onset: 30 minutes, duration 2-4 hours
     - Lowers K by 0.5-1 mEq/L
   - **Sodium bicarbonate** 50-100 mEq IV (if metabolic acidosis)
     - Controversial efficacy

3. **Remove K from body**:
   - **Loop diuretics** (furosemide 40-80 mg IV) if adequate kidney function
   - **Potassium binders**:
     - **Patiromer** 8.4-25.2 g PO daily (onset hours)
     - **Sodium zirconium cyclosilicate (SZC)** 10 g PO TID (onset 1-2 hours)
     - Sodium polystyrene sulfonate (Kayexalate): No longer recommended (limited efficacy, GI complications)
   - **Hemodialysis**: Most effective, definitive
     - Indications: Refractory hyperkalemia, severe CKD/ESRD, AKI with oliguria

**Mild to moderate hyperkalemia (no ECG changes)**:
- Discontinue K sources (dietary, medications, IV)
- Potassium binders (patiromer, SZC)
- Diuretics (if adequate kidney function)
- Address underlying cause

**Chronic management**:
- Low-potassium diet (<2-3 g/day)
- Avoid salt substitutes (KCl)
- Adjust medications: Lower dose or discontinue RAAS inhibitors (if necessary, but try to continue if CKD)
- Potassium binders if needed to allow continuation of RAAS inhibition

### Hypokalemia

**Definition**: Serum potassium <3.5 mEq/L

**Severity**:
- Mild: 3.0-3.4 mEq/L
- Moderate: 2.5-2.9 mEq/L
- Severe: <2.5 mEq/L

#### Pathophysiology

**Mechanisms**:
- Decreased intake (rare as sole cause)
- Transcellular shift (K moves into cells)
- Increased losses (renal or GI)

**Causes**:

*Transcellular shift*:
- Insulin
- Beta-2 agonists (albuterol)
- Alkalosis (metabolic or respiratory)
- Hypokalemic periodic paralysis
- Refeeding syndrome
- Hypothermia

*GI losses*:
- Diarrhea (most common GI cause)
- Vomiting (also generates metabolic alkalosis, which worsens hypokalemia)
- Laxative abuse
- VIPoma
- Urine K <20 mEq/day

*Renal losses*:
- **Diuretics** (most common overall cause):
  - Loop diuretics (furosemide)
  - Thiazide diuretics
- **Hyperaldosteronism**:
  - Primary: Adrenal adenoma (Conn syndrome), bilateral adrenal hyperplasia
  - Secondary: Renovascular hypertension, renin-secreting tumor
- **Hypomagnesemia**: Impairs K reabsorption (must correct Mg to correct K)
- **Renal tubular acidosis** (Type 1 and 2)
- **Bartter and Gitelman syndromes**: Genetic tubular defects
- **Medications**: Amphotericin B, cisplatin, foscarnet, aminoglycosides
- **Osmotic diuresis**: Hyperglycemia
- Urine K >20 mEq/day

*Decreased intake*:
- Poor oral intake, malnutrition
- TPN without adequate K

#### Clinical Presentation

**Cardiac**:
- Arrhythmias (especially if on digoxin or underlying heart disease)
- **ECG changes**:
  - Flattened or inverted T waves
  - Prominent U waves
  - ST depression
  - Prolonged QT interval
  - Premature ventricular contractions

**Neuromuscular**:
- Muscle weakness (legs > arms)
- Cramps, myalgias
- Constipation, ileus
- Rhabdomyolysis (severe)
- Ascending paralysis (severe)
- Respiratory muscle weakness (severe)

**Renal**:
- Polyuria, polydipsia (impaired concentrating ability)

**Often asymptomatic** if mild

#### Diagnosis

**Evaluate cause**:
- **Urine potassium**: 24-hour urine or spot urine K
  - <20 mEq/day: Extrarenal losses (GI), transcellular shift, decreased intake
  - >20 mEq/day: Renal losses (diuretics, hyperaldosteronism, RTA, Mg deficiency)
- **Acid-base status**: Metabolic alkalosis (vomiting, diuretics) vs acidosis (RTA, diarrhea)
- **Blood pressure**: Hypertension suggests hyperaldosteronism
- **Magnesium level**: Check and correct if low
- **Medications**: Review diuretics, laxatives

**If hyperaldosteronism suspected**:
- Plasma aldosterone and renin levels (aldosterone:renin ratio)
- Adrenal imaging

#### Treatment

**General principles**:
- **Correct hypomagnesemia first** (if present, K will not correct otherwise)
- Oral replacement preferred (safer, more physiologic)
- IV replacement if severe, symptomatic, or unable to take PO

**Oral replacement**:
- **Potassium chloride (KCl)**: 40-100 mEq/day in divided doses
- Each 10 mEq raises serum K by ~0.1 mEq/L
- Goal: K >3.5 mEq/L

**IV replacement** (if severe or symptomatic):
- Peripheral line: Maximum 10 mEq/hr, concentration ≤40 mEq/L (irritates veins)
- Central line: Can give higher rates (20 mEq/hr) and concentrations if needed
- Monitor: Continuous ECG, frequent K checks
- Maximum ~200-400 mEq in 24 hours

**Chronic management**:
- **Potassium-rich diet**: Bananas, oranges, potatoes, spinach
- **Potassium-sparing diuretics**: Spironolactone, amiloride (if on loop/thiazide diuretics)
- **ACE-I or ARBs**: Reduce renal K wasting (if appropriate for BP)

## Calcium Disorders

### Hypercalcemia

**Definition**: Serum calcium >10.5 mg/dL (total) or ionized calcium >5.3 mg/dL

**Corrected calcium** = Measured Ca + [0.8 × (4.0 - albumin)]
- Necessary because calcium is bound to albumin; correct if albumin abnormal

#### Pathophysiology

**Mechanisms**:
- Increased bone resorption
- Increased GI absorption
- Decreased renal excretion

**Causes** (PTH is key to diagnosis):

*PTH-mediated (elevated PTH)*:
- **Primary hyperparathyroidism** (most common outpatient cause):
  - Parathyroid adenoma (80%), hyperplasia (15%), carcinoma (<1%)
- **Familial hypocalciuric hypercalcemia (FHH)**: Benign, genetic, no treatment needed
- Tertiary hyperparathyroidism (CKD)
- Lithium use

*Non-PTH-mediated (suppressed PTH)*:
- **Malignancy** (most common inpatient cause):
  - Humoral hypercalcemia: PTHrP secretion (lung, kidney, breast cancers)
  - Lytic bone metastases (multiple myeloma, breast cancer)
  - Lymphoma (1,25-dihydroxyvitamin D production)
- **Vitamin D intoxication**: Excessive supplementation
- **Granulomatous diseases**: Sarcoidosis, tuberculosis (1,25-dihydroxyvitamin D)
- **Medications**: Thiazide diuretics, calcium supplements, vitamin D, vitamin A
- **Immobilization**: Increased bone resorption
- **Hyperthyroidism**: Increased bone turnover
- **Milk-alkali syndrome**: Excessive calcium carbonate intake (antacids)

#### Clinical Presentation

**"Stones, bones, abdominal groans, psychiatric moans"**

**Symptoms** (correlate with severity and acuity):
- Mild (<12 mg/dL): Often asymptomatic
- **Renal**: Polyuria, polydipsia (nephrogenic DI), kidney stones, nephrocalcinosis
- **GI**: Nausea, vomiting, constipation, pancreatitis
- **Neurologic**: Fatigue, weakness, confusion, lethargy, coma
- **Cardiac**: Bradycardia, arrhythmias, hypertension
  - **ECG**: Shortened QT interval
- **Musculoskeletal**: Bone pain, fractures (hyperparathyroidism)

**Hypercalcemic crisis** (severe, >14 mg/dL):
- Altered mental status, coma
- Acute kidney injury
- Cardiac arrhythmias
- Medical emergency

#### Diagnosis

**Initial tests**:
- Serum calcium (total and ionized), albumin (calculate corrected Ca)
- **PTH**: Key to diagnosis
- Phosphate: Low in hyperparathyroidism, high in malignancy
- BUN, creatinine
- 25-hydroxyvitamin D
- PTHrP (if malignancy suspected, PTH suppressed)

**Additional tests based on etiology**:
- Serum and urine protein electrophoresis (multiple myeloma)
- 1,25-dihydroxyvitamin D (granulomatous disease)
- TSH (hyperthyroidism)
- Parathyroid imaging (sestamibi scan, ultrasound) if primary hyperparathyroidism

#### Treatment

**Severity determines urgency**

**Acute severe hypercalcemia (>14 mg/dL or symptomatic)**:

1. **IV fluids**: Normal saline 200-300 mL/hr
   - Rehydrate, promote calciuresis
   - Goal urine output 100-150 mL/hr
   - Most important initial step

2. **Calcitonin**: 4 IU/kg SC/IM every 12 hours
   - Onset: 4-6 hours (fastest)
   - Lowers Ca by 1-2 mg/dL
   - Tachyphylaxis develops (effect diminishes after 48 hours)

3. **Bisphosphonates** (inhibit bone resorption):
   - **Zoledronic acid** 4 mg IV over 15-30 minutes (preferred)
   - **Pamidronate** 60-90 mg IV over 2-4 hours
   - Onset: 2-4 days (slow), duration weeks
   - Dose-adjust for renal function

4. **Loop diuretics** (furosemide): Only after adequate hydration
   - Promotes calciuresis
   - Monitor electrolytes (hypokalemia, hypomagnesemia)

5. **Dialysis**: If refractory or severe kidney disease

6. **Treat underlying cause**

**Mild to moderate hypercalcemia**:
- Hydration
- Treat underlying cause:
  - **Primary hyperparathyroidism**: Parathyroidectomy (definitive)
    - Indications: Ca >1 mg/dL above ULN, age <50, osteoporosis, kidney stones, GFR <60
  - **Malignancy**: Treat cancer
  - **Vitamin D toxicity**: Stop vitamin D

**Chronic management**:
- Avoid thiazides, dehydration
- Low calcium diet (if appropriate)
- Bisphosphonates (if malignancy)

### Hypocalcemia

**Definition**: Serum calcium <8.5 mg/dL (total) or ionized calcium <4.7 mg/dL

#### Pathophysiology

**Causes**:

*Hypoparathyroidism*:
- Post-surgical (thyroidectomy, parathyroidectomy)
- Autoimmune
- Genetic (DiGeorge syndrome)
- Hypomagnesemia (functional hypoparathyroidism)
- Infiltrative diseases

*Vitamin D deficiency*:
- Nutritional
- Malabsorption
- CKD (reduced 1,25-dihydroxyvitamin D production)

*PTH resistance*:
- Pseudohypoparathyroidism (genetic)

*Other*:
- **Acute pancreatitis**: Calcium sequestration in necrotic fat
- **Tumor lysis syndrome**: Hyperphosphatemia → Ca-PO4 precipitation
- **Hungry bone syndrome**: After parathyroidectomy in severe hyperparathyroidism
- **Medications**: Bisphosphonates, denosumab, foscarnet, cinacalcet
- **Massive blood transfusion**: Citrate binds calcium
- **Sepsis**, **rhabdomyolysis**

#### Clinical Presentation

**Neuromuscular** (increased excitability):
- **Paresthesias**: Perioral, fingers, toes
- **Muscle cramps**, tetany
- **Chvostek sign**: Facial twitching with tapping facial nerve
- **Trousseau sign**: Carpopedal spasm with BP cuff inflation
- **Seizures** (severe)
- **Laryngospasm**, **bronchospasm** (severe, life-threatening)

**Cardiac**:
- **ECG**: Prolonged QT interval
- Arrhythmias (torsades de pointes)
- Hypotension, heart failure

**Psychiatric**: Anxiety, irritability, depression, psychosis

**Chronic**: Cataracts, dry skin, brittle nails

#### Diagnosis

**Initial tests**:
- Serum calcium (total and ionized), albumin (corrected Ca)
- **PTH**: Elevated (appropriate) vs low/normal (inappropriate)
- **Phosphate**: High in hypoparathyroidism, low in vitamin D deficiency
- **Magnesium**: Check (hypomagnesemia causes hypocalcemia)
- **25-hydroxyvitamin D** (nutritional status)
- **1,25-dihydroxyvitamin D** (if CKD)
- BUN, creatinine (kidney function)
- ECG

#### Treatment

**Severe symptomatic hypocalcemia** (tetany, seizures, prolonged QT):

1. **IV calcium**: 1-2 amps calcium gluconate 10% (10-20 mL) IV over 10-20 minutes
   - Rapid effect
   - Repeat as needed for symptoms
   - Then continuous infusion: 5-10 amps calcium gluconate in 1 L D5W at 50 mL/hr

2. **Magnesium replacement** (if low): Magnesium sulfate 2 g IV over 15 minutes

3. **Monitor**: Calcium q4-6h, ECG

**Mild to moderate hypocalcemia**:
- **Oral calcium**: Calcium carbonate 1-3 g elemental calcium/day in divided doses
- **Vitamin D**:
  - Ergocalciferol or cholecalciferol 50,000 IU weekly if deficiency
  - **Calcitriol** 0.25-0.5 mcg BID (active vitamin D, if hypoparathyroidism or CKD)
- **Magnesium** replacement if low

**Chronic management** (hypoparathyroidism):
- Calcium 1-3 g/day + calcitriol 0.25-2 mcg/day
- Goal: Low-normal calcium (avoid hypercalciuria, nephrolithiasis)
- Monitor: Serum calcium, urine calcium

## Key Points

- Hyponatremia is classified by volume status and serum osmolality; SIADH is the most common cause of euvolemic hypotonic hyponatremia
- Acute symptomatic hyponatremia requires urgent treatment with 3% hypertonic saline, but chronic hyponatremia must be corrected slowly (6-8 mEq/L in 24 hours) to avoid osmotic demyelination syndrome
- Hypernatremia always indicates water deficit; treatment involves calculating and replacing free water deficit, correcting slowly (0.5 mEq/L/hr, <10 mEq/L in 24 hours)
- Severe hyperkalemia with ECG changes is a medical emergency treated with calcium gluconate (stabilize membrane), insulin + dextrose and albuterol (shift K into cells), and hemodialysis (remove K)
- Hypokalemia refractory to replacement should prompt evaluation for hypomagnesemia, which must be corrected to allow potassium repletion
- Hypercalcemia is diagnosed by measuring PTH: elevated in primary hyperparathyroidism, suppressed in malignancy (most common inpatient cause)
- Acute severe hypercalcemia is treated with IV fluids (normal saline), calcitonin (fastest onset), and bisphosphonates (most sustained effect)
- Severe symptomatic hypocalcemia (tetany, seizures) requires IV calcium gluconate; chronic management of hypoparathyroidism requires oral calcium plus calcitriol
- FENa <1% indicates prerenal AKI, while FENa >2% suggests intrinsic renal disease (ATN); this is useful in evaluating acute kidney injury
- Urine osmolality helps diagnose hyponatremia: <100 mOsm/kg suggests primary polydipsia, >100 mOsm/kg with elevated urine sodium suggests SIADH

## References

1. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1-47.

2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-42.

3. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10(11):653-662.

4. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.

5. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10(6):1050-1060.

6. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-3569.

7. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-379.

8. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298-1302.
